Calcipotriol


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Topical Mild to moderate plaque psoriasis As 0.005% cream/oint: Apply to the affected area 1-2 times/day. Max: 100 g/wk. Scalp psoriasis As 0.005% soln: Apply to the affected area bid. Max: 60 mL/wk. If used together, a Max of 5 mg of the drug per wk.
Dosage Details
Topical/Cutaneous
Mild to moderate plaque psoriasis
Adult: As 0.005% cream/oint: Apply a thin layer and rub in gently and completely to the affected area 1-2 times daily. Max: 100 g/wk; if used together w/ scalp soln, 5 mg of the drug per wk (e.g. cream/oint 60 g w/ scalp soln 40 mL or cream/oint 40 g w/ scalp soln 60 mL).
Child: As 0.005% oint: Apply bid. Max: 6-12 yr 50 g/wk; >12 yr 75 g/wk. Max duration: 8 wk.

Topical/Cutaneous
Scalp psoriasis
Adult: As 0.005% soln: Apply and rub in gently and completely to the affected area bid. Avoid contact w/ the forehead or uninvolved scalp margin. Max: 60 mL/wk; if used together w/ cream/oint, 5 mg of the drug per wk (e.g. cream/oint 60 g w/ scalp soln 40 mL or cream/oint 40 g w/ scalp soln 60 mL).
Renal Impairment
Severe: Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
Contraindications
Hypercalcaemia, Ca metabolism disorder. Acute psoriatic eruptions (scalp soln). Severe renal or hepatic impairment.
Special Precautions
Patient w/ erythrodermic exfoliative psoriasis, generalised pustular psoriasis. Pregnancy and lactation.
Adverse Reactions
Skin irritation, burning, itching, erythema, and dryness; eczema, contact dermatitis, aggravated psoriasis; hypercalcaemia, hypercalciruria. Rarely, skin atrophy, hyperpigmentation, photosensitivity.
Patient Counseling Information
Avoid application to the face, eyes, or mucous membranes. Avoid exposure to natural or artificial sunlight.
MonitoringParameters
Monitor serum Ca.
Drug Interactions
Inactivated by salicylic acid externals.
Action
Description: Calcipotriol, a synthetic vit D3 derivative, is an antipsoriatic agent. It binds to vit D receptors to induce differentiation and supress proliferation of keratinocytes.
Onset: 2 wk; marked improvement seen after 8 wk.
Pharmacokinetics:
Absorption: <1% is absorbed when applied to psoriasis plaques (soln); approx 6% is absorbed (oint).
Metabolism: Rapidly metabolised into inactive metabolites.
Chemical Structure

Chemical Structure Image
Calcipotriol

Source: National Center for Biotechnology Information. PubChem Database. Calcipotriol, CID=5288783, https://pubchem.ncbi.nlm.nih.gov/compound/Calcipotriol (accessed on Jan. 21, 2020)

Storage
Store between 15-25°C. Do not freeze. Soln: Keep away from sunlight or open flame.
ATC Classification
D05AX02 - calcipotriol ; Belongs to the class of other antipsoriatics for topical use.
References
Anon. Calcipotriene. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/11/2016.

Buckingham R (ed). Calcipotriol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2016.

Calcipotriene Cream (Sandoz Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/11/2016.

Calcipotriene Ointment (Prasco Laboratories). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/11/2016.

Calcipotriene Solution (Impax Generics). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/11/2016.

Joint Formulary Committee. Calcipotriol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2016.

Leo Pharma Ltd. Daivonex Ointment data sheet January 2016. Medsafe. http://www.medsafe.govt.nz/. Accessed 10/11/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Calcipotriene (Topical). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/11/2016.

Disclaimer: This information is independently developed by MIMS based on Calcipotriol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in